Pathology: mNSCLC - L1 - all population; mNSCLC - L1 - PDL1 positive; mNSCLC - L1 - TMB>10Mb;
mNSCLC - L1 - all population | mNSCLC - L1 - PDL1 positive | mNSCLC - L1 - TMB>10Mb | ||
CheckMate 9LA, 2021 | CheckMate 227 (NI vs C ; PDL1>1%), 2018 | CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 | ||
nivolumab plus ipilimumab | 2 | T1 | T1 | |
nivolumab plus ipilimumab plus SoC | 1 | T1 | ||
Standard of Care (SoC) | 0 | T0 | ||
pemetrexed plus platin | 0 | T0 | T0 |